Oleoma Treated with Oral Colchicine: Report of Two Cases and Review of the Literature
Overview
Authors
Affiliations
Oleoma is a non-allergic, foreign body type granulomatous reaction. It appears as response to oily exogenous substances injected to the dermis or subcutis for aesthetical purposes. Treatment for localized lesions is surgical. When they are multiple, steroids may show some result. Newer therapeutic possibilities are being introduced and colchicine constitutes an alternative that is financially accessible and safe in moderate doses for certain dermatological illnesses. We present two women with oleoma on the legs treated with oral colchicine. This option was due to the extension of the clinical picture, which would not have a good surgical outcome. There was significant improvement in one patient, while we had to interrupt the medication in the other because of side effects.
Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients.
Montealegre-Gomez G, Garavito E, Gomez-Lopez A, Rojas-Villarraga A, Parra-Medina R Reumatol Clin. 2024; 17(7):371-375.
PMID: 38620275 PMC: 7229928. DOI: 10.1016/j.reuma.2020.05.001.
Progressively worsening painful sclerotic calf plaques.
Burger E, Hinds B, Paravar T JAAD Case Rep. 2023; 34:94-96.
PMID: 37009034 PMC: 10063376. DOI: 10.1016/j.jdcr.2023.02.003.
Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence.
Cimmino G, Loffredo F, De Rosa G, Cirillo P Int J Mol Sci. 2023; 24(3).
PMID: 36768804 PMC: 9917272. DOI: 10.3390/ijms24032483.
Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients.
Montealegre-Gomez G, Garavito E, Gomez-Lopez A, Rojas-Villarraga A, Parra-Medina R Reumatol Clin (Engl Ed). 2021; 17(7):371-375.
PMID: 34301378 PMC: 8290220. DOI: 10.1016/j.reumae.2020.05.008.
ASIA syndrome symptoms induced by gluteal biopolymer injections: Case-series and narrative review.
Montealegre G, Uribe R, Martinez-Ceballos M, Rojas-Villarraga A Toxicol Rep. 2021; 8:303-314.
PMID: 33552929 PMC: 7856393. DOI: 10.1016/j.toxrep.2021.01.011.